Your browser doesn't support javascript.
loading
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
Cahn, Avivit; Wiviott, Stephen D; Mosenzon, Ofri; Murphy, Sabina A; Goodrich, Erica L; Yanuv, Ilan; Rozenberg, Aliza; Wilding, John P H; Leiter, Lawrence A; Bhatt, Deepak L; McGuire, Darren K; Litwak, Leon; Kooy, Adriaan; Gause-Nilsson, Ingrid A M; Fredriksson, Martin; Langkilde, Anna Maria; Sabatine, Marc S; Raz, Itamar.
Affiliation
  • Cahn A; Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.
  • Wiviott SD; Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Mosenzon O; Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Murphy SA; Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.
  • Goodrich EL; Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Yanuv I; Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Rozenberg A; Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Wilding JPH; Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.
  • Leiter LA; Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.
  • Bhatt DL; Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
  • McGuire DK; Department of Medicine, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Canada.
  • Litwak L; Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Kooy A; Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas.
  • Gause-Nilsson IAM; Endocrinology Unit, Diabetes Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Fredriksson M; University Medical Center Groningen and Bethesda Diabetes Research Center, Groningen, the Netherlands.
  • Langkilde AM; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Sabatine MS; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Raz I; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Diabetes Obes Metab ; 23(1): 29-38, 2021 01.
Article in En | MEDLINE | ID: mdl-32844557
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Brain Ischemia / Stroke / Diabetes Mellitus, Type 2 Type of study: Clinical_trials Limits: Humans Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2021 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Brain Ischemia / Stroke / Diabetes Mellitus, Type 2 Type of study: Clinical_trials Limits: Humans Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2021 Document type: Article Affiliation country: Country of publication: